Literature DB >> 2829371

Itraconazole in the treatment of acute vaginal candidiasis.

B Bloch1, P G Barnard, G D Burger, J S Meyer, J R Parkes, E Smythe.   

Abstract

In a multicentre open prospective study itraconazole was evaluated in the treatment of acute vaginal candidiasis. Two dosage regimens were tested--200 mg twice a day for 1 day and 200 mg twice a day for 2 days. There were no statistically significant differences between these dosages, and cure rates at 7 and 28 days after treatment were 83% and 75% respectively. These are marginally lower than those produced by longer courses of oral ketoconazole (Nizoral; Janssen) and vaginal econazole nitrate but the advantages are better patient compliance and greater cost-effectiveness.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2829371

Source DB:  PubMed          Journal:  S Afr Med J


  4 in total

1.  Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.

Authors:  R F Hector; E Yee
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

2.  A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole.

Authors:  Marc Francois; Eric Snoeckx; Peter Putteman; Fons Wouters; Eddy De Proost; Urbain Delaet; Jef Peeters; Marcus E Brewster
Journal:  AAPS PharmSci       Date:  2003

3.  A novel itraconazole bioadhesive film for vaginal delivery: design, optimization, and physicodynamic characterization.

Authors:  Nitin B Dobaria; A C Badhan; R C Mashru
Journal:  AAPS PharmSciTech       Date:  2009-07-24       Impact factor: 3.246

4.  Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis.

Authors:  G E Stein; N Mummaw
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.